Home 
Acta Virologica 2021 Acta Virologica Vol.65, No.1, p.82-88, 2021
Acta Virologica 2021 Acta Virologica Vol.65, No.1, p.82-88, 2021
Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Current articles 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Acta Virologica Vol.65, No.1, p.82-88, 2021 |
||
| Title: Optimization of a cellular HBV infection model for use in high-throughput drug screening | ||
| Author: Nadezhda P. Kartashova, Svetlana I. Iarovenko, Ekaterina A. Glubokova, Ilya A. Potemkin, Anastasia A. Karlsen, Irina A. Leneva, Karen K. Kyuregyan, Alexey A. Ryakhovskiy, Mikhail I. Mikhailov | ||
| Abstract: Hepatitis B virus (HBV) is a partially double-stranded DNA virus that specifically targets hepatocytes. It is considered a major health issue due to its high prevalence and the life-threatening consequences of chronic infection, including liver cirrhosis and hepatocellular carcinoma. Despite widespread vaccination against HBV, millions of people live with chronic HBV infection. Existing antiviral therapies fail to achieve full HBV elimination, so most patients with the disease require lifelong treatment. The search for new antiviral therapy strategies is hindered by the limited availability of in vitro HBV infection models that are able to support the full HBV life cycle. Therefore, the development and optimization of cellular models are crucial to the search for drugs effective against HBV. In this study, we optimized an in vitro HBV infection model consisting of two cell lines: HepAD38 cells, which are able to produce infectious HBV; and HepG2-NTCP cells, which are susceptible to HBV infection. We showed that prolonged production of HBV in the “donor” cells and HBV inoculation of the “acceptor” cells simultaneously with seeding improves the established procedure. This modified protocol was proven effective in experiments involving compounds with known activity against HBV, suggesting its utility for future high-throughput screening. |
||
| Keywords: HBV; HBV in vitro models; HepG2-NTCP; HepAD38 | ||
| Published online: 23-Feb-2021 | ||
| Year: 2021, Volume: 65, Issue: 1 | Page From: 82, Page To: 88 | |
| doi:10.4149/av_2021_110 |
||
|
|
 download file |
|